Skip to main content
Top
Published in: Pituitary 6/2023

21-09-2023

Clinical and prognostic significance of granulation patterns in somatotroph adenomas/tumors of the pituitary: a meta-analysis

Authors: Huy Gia Vuong, Ian F. Dunn

Published in: Pituitary | Issue 6/2023

Login to get access

Abstract

Introduction

Sparsely granulated somatotroph adenoma/tumor (SGST) is thought to be more clinically aggressive than densely granulated somatotroph adenoma/tumor (DGST). However, the literature is not entirely consistent as to the disparate demographic and behavioral features of these subtypes. In this study, we conducted a meta-analysis to further clarify the demographic, clinicopathological, prognostic, and molecular characteristics of SGST versus DGST.

Methods

We accessed two electronic databases to search for potential data. Pooled estimates of odds ratio (OR), mean difference (MD), and corresponding 95% confidence interval (CI) were calculated using the random-effect model.

Results

SGST was associated with younger patient age and lower male-to-female ratio (p < 0.001) compared to DGST. Clinically, SGST had larger tumor size and high rate of cavernous sinus and suprasellar extension (p < 0.001) than DGST. During postoperative follow-up, SGST was associated with a lower endocrinological remission rate (OR 0.60; 95% CI 0.40 to 0.90; p = 0.01) and a poorer response rate to SRL (OR 0.16; 95% CI 0.08–0.35; p < 0.001) in comparison to DGST. The prevalence of GSP mutations was significantly lower in SGST (OR 0.36; 95% CI 0.17 to 0.79; p = 0.01).

Conclusion

SGST and DGST were demographically, clinicopathologically, and molecularly different from each other with the former associated with adverse treatment outcomes and poor response to medical therapy. There are still gaps in translational studies that could help us better understand the behavior of these tumors and identify potential targets in the treatment of sparsely granulated tumors.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mete O, Lopes MB (2017) Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol 28(3):228–243CrossRefPubMed Mete O, Lopes MB (2017) Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol 28(3):228–243CrossRefPubMed
2.
go back to reference Yamada S, Aiba T, Sano T et al (1993) Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology. Neurosurgery 33(1):20–27PubMed Yamada S, Aiba T, Sano T et al (1993) Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology. Neurosurgery 33(1):20–27PubMed
3.
go back to reference Obari A, Sano T, Ohyama K et al (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19(2):82–91CrossRefPubMed Obari A, Sano T, Ohyama K et al (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19(2):82–91CrossRefPubMed
4.
go back to reference Melmed S, Braunstein GD, Horvath E, Ezrin C, Kovacs K (1983) Pathophysiology of acromegaly. Endocr Rev 4(3):271–290CrossRefPubMed Melmed S, Braunstein GD, Horvath E, Ezrin C, Kovacs K (1983) Pathophysiology of acromegaly. Endocr Rev 4(3):271–290CrossRefPubMed
5.
go back to reference Bakhtiar Y, Hirano H, Arita K et al (2010) Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae. Eur J Endocrinol 163(4):531–539CrossRefPubMed Bakhtiar Y, Hirano H, Arita K et al (2010) Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae. Eur J Endocrinol 163(4):531–539CrossRefPubMed
6.
go back to reference Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M (2013) Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary 16(4):490–498CrossRefPubMed Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M (2013) Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary 16(4):490–498CrossRefPubMed
7.
go back to reference Kato M, Inoshita N, Sugiyama T et al (2012) Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocr J 59(3):221–228CrossRefPubMed Kato M, Inoshita N, Sugiyama T et al (2012) Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocr J 59(3):221–228CrossRefPubMed
8.
go back to reference Mori R, Inoshita N, Takahashi-Fujigasaki J et al (2013) Clinicopathological features of growth hormone-producing pituitary adenomas in 242 acromegaly patients: classification according to hormone production and cytokeratin distribution. ISRN Endocrinol 2013:723432CrossRefPubMedPubMedCentral Mori R, Inoshita N, Takahashi-Fujigasaki J et al (2013) Clinicopathological features of growth hormone-producing pituitary adenomas in 242 acromegaly patients: classification according to hormone production and cytokeratin distribution. ISRN Endocrinol 2013:723432CrossRefPubMedPubMedCentral
9.
go back to reference Larkin S, Reddy R, Karavitaki N, Cudlip S, Wass J, Ansorge O (2013) Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. Eur J Endocrinol 168(4):491–499CrossRefPubMed Larkin S, Reddy R, Karavitaki N, Cudlip S, Wass J, Ansorge O (2013) Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. Eur J Endocrinol 168(4):491–499CrossRefPubMed
10.
go back to reference Lee CC, Vance ML, Lopes MB, Xu Z, Chen CJ, Sheehan J (2015) Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype. Pituitary 18(3):326–334CrossRefPubMed Lee CC, Vance ML, Lopes MB, Xu Z, Chen CJ, Sheehan J (2015) Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype. Pituitary 18(3):326–334CrossRefPubMed
11.
go back to reference Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S (2005) The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 90(11):6290–6295CrossRefPubMed Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S (2005) The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 90(11):6290–6295CrossRefPubMed
12.
go back to reference Sarkar S, Chacko AG, Chacko G (2014) An analysis of granulation patterns, MIB-1 proliferation indices and p53 expression in 101 patients with acromegaly. Acta Neurochir. 156(12):2221–2230 (discussion 2230)CrossRefPubMed Sarkar S, Chacko AG, Chacko G (2014) An analysis of granulation patterns, MIB-1 proliferation indices and p53 expression in 101 patients with acromegaly. Acta Neurochir. 156(12):2221–2230 (discussion 2230)CrossRefPubMed
13.
go back to reference Fougner SL, Casar-Borota O, Heck A, Berg JP, Bollerslev J (2012) Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol 76(1):96–102CrossRef Fougner SL, Casar-Borota O, Heck A, Berg JP, Bollerslev J (2012) Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol 76(1):96–102CrossRef
14.
go back to reference Giustina A, Chanson P, Bronstein MD et al (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95(7):3141–3148CrossRefPubMed Giustina A, Chanson P, Bronstein MD et al (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95(7):3141–3148CrossRefPubMed
15.
go back to reference Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558CrossRefPubMed Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558CrossRefPubMed
16.
go back to reference Vuong HG, Dunn IF (2023) The clinicopathological features and prognosis of silent corticotroph tumors: an updated systematic review and meta-analysis. Endocrine Vuong HG, Dunn IF (2023) The clinicopathological features and prognosis of silent corticotroph tumors: an updated systematic review and meta-analysis. Endocrine
17.
go back to reference Dehghani M, Davoodi Z, Bidari F et al (2021) Association of different pathologic subtypes of growth hormone producing pituitary adenoma and remission in acromegaly patients: a retrospective cohort study. BMC Endocr Disord 21(1):186CrossRefPubMedPubMedCentral Dehghani M, Davoodi Z, Bidari F et al (2021) Association of different pathologic subtypes of growth hormone producing pituitary adenoma and remission in acromegaly patients: a retrospective cohort study. BMC Endocr Disord 21(1):186CrossRefPubMedPubMedCentral
18.
go back to reference Durmuş ET, Atmaca A, Kefeli M et al (2022) Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: a clinicopathological study. Growth Horm IGF Res 67:101502CrossRefPubMed Durmuş ET, Atmaca A, Kefeli M et al (2022) Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: a clinicopathological study. Growth Horm IGF Res 67:101502CrossRefPubMed
19.
go back to reference Heng L, Liu X, Jia D et al (2021) Preoperative prediction of granulation pattern subtypes in GH-secreting pituitary adenomas. Clin Endocrinol 95(1):134–142CrossRef Heng L, Liu X, Jia D et al (2021) Preoperative prediction of granulation pattern subtypes in GH-secreting pituitary adenomas. Clin Endocrinol 95(1):134–142CrossRef
20.
go back to reference Iacovazzo D, Carlsen E, Lugli F et al (2016) Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol 174(2):241–250CrossRefPubMed Iacovazzo D, Carlsen E, Lugli F et al (2016) Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol 174(2):241–250CrossRefPubMed
21.
go back to reference Kasuki L, Wildemberg LE, Neto LV, Marcondes J, Takiya CM, Gadelha MR (2013) Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern. Eur J Endocrinol 169(2):217–223CrossRefPubMed Kasuki L, Wildemberg LE, Neto LV, Marcondes J, Takiya CM, Gadelha MR (2013) Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern. Eur J Endocrinol 169(2):217–223CrossRefPubMed
22.
go back to reference Park YW, Kang Y, Ahn SS et al (2020) Radiomics model predicts granulation pattern in growth hormone-secreting pituitary adenomas. Pituitary 23(6):691–700CrossRefPubMed Park YW, Kang Y, Ahn SS et al (2020) Radiomics model predicts granulation pattern in growth hormone-secreting pituitary adenomas. Pituitary 23(6):691–700CrossRefPubMed
23.
go back to reference Soukup J, Cesak T, Hornychova H et al (2021) Cytokeratin 8/18-negative somatotroph pituitary neuroendocrine tumours (PitNETs, adenomas) show variable morphological features and do not represent a clinicopathologically distinct entity. Histopathology 79(3):406–415CrossRefPubMed Soukup J, Cesak T, Hornychova H et al (2021) Cytokeratin 8/18-negative somatotroph pituitary neuroendocrine tumours (PitNETs, adenomas) show variable morphological features and do not represent a clinicopathologically distinct entity. Histopathology 79(3):406–415CrossRefPubMed
24.
go back to reference Swanson AA, Erickson D, Donegan DM et al (2021) Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly. Pituitary 24(2):192–206CrossRefPubMed Swanson AA, Erickson D, Donegan DM et al (2021) Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly. Pituitary 24(2):192–206CrossRefPubMed
25.
go back to reference Tang Y, Xie T, Wu S et al (2021) Quantitative proteomics revealed the molecular characteristics of distinct types of granulated somatotroph adenomas. Endocrine 74(2):375–386CrossRefPubMed Tang Y, Xie T, Wu S et al (2021) Quantitative proteomics revealed the molecular characteristics of distinct types of granulated somatotroph adenomas. Endocrine 74(2):375–386CrossRefPubMed
26.
go back to reference Mayr B, Buslei R, Theodoropoulou M, Stalla GK, Buchfelder M, Schöfl C (2013) Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas. Eur J Endocrinol 169(4):391–400CrossRefPubMed Mayr B, Buslei R, Theodoropoulou M, Stalla GK, Buchfelder M, Schöfl C (2013) Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas. Eur J Endocrinol 169(4):391–400CrossRefPubMed
29.
go back to reference Florio T, Morini M, Villa V et al (2003) Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 144(4):1574–1584CrossRefPubMed Florio T, Morini M, Villa V et al (2003) Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 144(4):1574–1584CrossRefPubMed
30.
go back to reference Gadelha MR, Kasuki L, Korbonits M (2013) Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab 24(5):238–246CrossRefPubMed Gadelha MR, Kasuki L, Korbonits M (2013) Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab 24(5):238–246CrossRefPubMed
31.
go back to reference Córdoba-Chacón J, Gahete MD, Duran-Prado M et al (2010) Identification and characterization of new functional truncated variants of somatostatin receptor subtype 5 in rodents. Cell Mol Life Sci 67(7):1147–1163CrossRefPubMed Córdoba-Chacón J, Gahete MD, Duran-Prado M et al (2010) Identification and characterization of new functional truncated variants of somatostatin receptor subtype 5 in rodents. Cell Mol Life Sci 67(7):1147–1163CrossRefPubMed
32.
go back to reference Durán-Prado M, Gahete MD, Martínez-Fuentes AJ et al (2009) Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J Clin Endocrinol Metab 94(7):2634–2643CrossRefPubMed Durán-Prado M, Gahete MD, Martínez-Fuentes AJ et al (2009) Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J Clin Endocrinol Metab 94(7):2634–2643CrossRefPubMed
33.
go back to reference Sano T, Rong QZ, Kagawa N, Yamada S (2004) Down-regulation of E-cadherin and catenins in human pituitary growth hormone-producing adenomas. Front Horm Res 32:127–132CrossRefPubMed Sano T, Rong QZ, Kagawa N, Yamada S (2004) Down-regulation of E-cadherin and catenins in human pituitary growth hormone-producing adenomas. Front Horm Res 32:127–132CrossRefPubMed
34.
go back to reference Qian ZR, Sano T, Yoshimoto K et al (2007) Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. Mod Pathol 20(12):1269–1277CrossRefPubMed Qian ZR, Sano T, Yoshimoto K et al (2007) Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. Mod Pathol 20(12):1269–1277CrossRefPubMed
35.
go back to reference Spada A, Arosio M, Bochicchio D et al (1990) Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab 71(6):1421–1426CrossRefPubMed Spada A, Arosio M, Bochicchio D et al (1990) Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab 71(6):1421–1426CrossRefPubMed
36.
go back to reference Efstathiadou ZA, Bargiota A, Chrisoulidou A et al (2015) Impact of gsp mutations in somatotroph pituitary adenomas on growth hormone response to somatostatin analogs: a meta-analysis. Pituitary 18(6):861–867CrossRefPubMed Efstathiadou ZA, Bargiota A, Chrisoulidou A et al (2015) Impact of gsp mutations in somatotroph pituitary adenomas on growth hormone response to somatostatin analogs: a meta-analysis. Pituitary 18(6):861–867CrossRefPubMed
37.
go back to reference Mazal PR, Czech T, Sedivy R et al (2001) Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of akromegalic patients. Clin Neuropathol 20(4):163-171 Mazal PR, Czech T, Sedivy R et al (2001) Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of akromegalic patients. Clin Neuropathol 20(4):163-171
Metadata
Title
Clinical and prognostic significance of granulation patterns in somatotroph adenomas/tumors of the pituitary: a meta-analysis
Authors
Huy Gia Vuong
Ian F. Dunn
Publication date
21-09-2023
Publisher
Springer US
Published in
Pituitary / Issue 6/2023
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-023-01353-0

Other articles of this Issue 6/2023

Pituitary 6/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine